NUTM1 and cancer: Ongoing phase I/II clinical trials are exploring targeted therapies to improve treatment options, combining bromodomain extra-terminal (BET) inhibitors and histone deacetylase inhibitors to displace BRD4-NUT fusion proteins from chromatin and thereby help to arrest cancer growth.